Efficacy and Safety of Curcumin and Curcuma longa Extract in the Treatment of Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trial

The short version

This systematic review and meta-analysis evaluates the efficacy and safety of curcumin and Curcuma longa extract across five types of arthritis: rheumatoid arthritis (RA), osteoarthritis (OA), ankylosing spondylitis (AS), juvenile idiopathic arthritis (JIA), and gout/hyperuricemia. Twenty-nine randomized controlled trials involving 2,396 participants were included, drawn from 11 countries. For RA (6 RCTs), curcumin significantly reduced disease activity (DAS28), ESR, CRP, and rheumatoid factor compared to controls. For OA (20 RCTs), curcumin reduced pain (VAS and WOMAC-pain), improved physical function, and decreased stiffness compared to placebo. Notably, curcumin showed comparable efficacy to NSAIDs (ibuprofen, diclofenac) with significantly fewer adverse events. For AS, a single RCT of nanocurcumin showed increased regulatory T cells and decreased IL-6. Two JIA trials found curcumin improved disease activity scores in children. Doses ranged from 120 to 1,500 mg daily for 4-36 weeks. The mechanisms of action include inhibition of NF-kB signaling, COX-2 suppression, NLRP3 inflammasome inhibition, and modulation of the RANK/RANKL/OPG system. Safety was favorable across all studies, with no serious adverse events attributed to curcumin. However, the evidence is limited by small sample sizes, short follow-up periods, high heterogeneity, and potential industry funding bias.

Key findings

• Curcumin (120-1500 mg/day) improved pain, inflammation markers (DAS28, ESR, CRP), and physical function across 5 types of arthritis in 29 RCTs
• For osteoarthritis, curcumin was comparable to NSAIDs (ibuprofen, diclofenac) in pain relief but with significantly fewer adverse events
• For rheumatoid arthritis, curcumin as an add-on to methotrexate reduced disease activity and inflammatory markers
• FDA GRAS status with good safety profile up to 8-12 g/day — most common side effect was mild GI discomfort
• Limitations: small sample sizes, short follow-up (max 16 weeks), moderate risk of bias due to industry funding in some trials